SYNERGISTIC ACTION OF CHOLERA-TOXIN B SUBUNIT (AND ESCHERICHIA-COLI HEAT-LABILE TOXIN-B SUBUNIT) AND A TRACE AMOUNT OF CHOLERA WHOLE TOXIN AS AN ADJUVANT FOR NASAL INFLUENZA VACCINE
被引:134
作者:
TAMURA, S
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
TAMURA, S
YAMANAKA, A
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
YAMANAKA, A
SHIMOHARA, M
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
SHIMOHARA, M
TOMITA, T
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
TOMITA, T
KOMASE, K
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
KOMASE, K
TSUDA, Y
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
TSUDA, Y
SUZUKI, Y
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
SUZUKI, Y
NAGAMINE, T
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
NAGAMINE, T
KAWAHARA, K
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
KAWAHARA, K
DANBARA, H
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
DANBARA, H
AIZAWA, C
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
AIZAWA, C
OYA, A
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
OYA, A
KURATA, T
论文数: 0引用数: 0
h-index: 0
机构:KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
KURATA, T
机构:
[1] KITASATO INST, DEPT TECHNOL, TOKYO 108, JAPAN
[2] UNIV TOKYO, INST MED SCI, DEPT BACTERIOL, TOKYO, JAPAN
CHOLERA TOXIN;
CHOLERA TOXIN B SUBUNIT;
ESCHERICHIA-COLI HEAT-LABILE TOXIN B SUBUNIT;
ADJUVANT;
NASAL VACCINE;
INFLUENZA;
D O I:
10.1016/0264-410X(94)90118-X
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Cholera toxin B subunit (CTB) and Escherichia coli heat-labile toxin (LTB) (2 mu g), each supplemented with a trace amount of cholera toxin (CT) (0.02-20 ng), were examined for the adjuvant effect on antibody (Ab) response against influenza inactivated HA (haemagglutinin) vaccine in Balb/c mice. Each mouse received a primary intranasal (i.n.) inoculation of the vaccine (1.5 mu g) and the CT-containing CTB and in 4 weeks a second i.n. inoculation of the vaccine alone. The primary inoculation of the vaccine with CTB alone did not induce either anti-HA IgA or IgG Ab response, or haemagglutination-inhibition Ab responses in the serum. The vaccine with less than 2 ng of CT also failed to induce Ab response. On the other hand, the vaccine with CT-containing CTB induced a high Ab response, which increased depending on the CT dose. Moreover, the second vaccine induced a response more than ten times higher than the primary one and the response increased depending on the CT dose. Similar enhancement was found in the local anti-HA IgA Ab response in the nasal wash. Such synergistic effects were observed also between LTB and CT. The amount of Ab produced by the synergism was considered to be enough to protect against virus infection. These results suggest that CTB (or LTB) containing a trace amount of CT (about 0.1%) can be used practically as a potent adjuvant for nasal vaccination of humans against influenza.